Phenotyping and endotyping asthma based on biomarkers

Current Topics in Medicinal Chemistry

Volumn 16, Issue 14, 2016, Pages 1582-1586

  Perlikos, Fotis ^a   Hillas, Giorgos ^a   Loukides, Stelios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Asthma; Biomarkers; Endotypes; Phenotypes; Response; Treatment

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; IMMUNOGLOBULIN E; INTERLEUKIN 13;

ALLERGIC ASTHMA; ARTICLE; ASTHMA; BODY FLUID; DISEASE COURSE; DISEASE EXACERBATION; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; IMMUNOTHERAPY; MYCOSIS BY BASIDIOMYCETES; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; QUALITY OF LIFE; SMOKING HABIT; SPUTUM; TH2 CELL; ENDOPHENOTYPE; GENETICS; METABOLISM;

ASTHMA; BIOMARKERS; ENDOPHENOTYPES; HUMANS; PHENOTYPE;

EID: 84964294858     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666150930120803     Document Type: Article

References (51)

1. Bateman, E. D.; Hurd, S. S.; Barnes, P. J.; Bousquet, J.; Drazen, J. M.; FitzGerald, M.; Gibson, P.; Ohta, K.; O'Byrne, P.; Pedersen, S. E.; Pizzichini, E.; Sullivan, S. D.; Wenzel, S. E.; Zar, H. J. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J., 2008, 31 (1), 143-78.
2. Agache, I. O. From phenotypes to endotypes to asthma treatment. Curr. Opin. Allergy Clin. Immunol., 2013, 13 (3), 249-56;
3. Szefler, S. J.; Martin, R. J.; King, T. S.; Boushey, H. A.; Cherniack, R. M.; Chinchilli, V. M.; Craig, T. J.; Dolovich, M.; Drazen, J. M.; Fagan, J. K.; Fahy, J. V.; Fish, J. E.; Ford, J. G.; Israel, E.; Kiley, J.; Kraft, M.; Lazarus, S. C.; Lemanske, R. F., Jr.; Mauger, E.; Peters, S. P.; Sorkness, C. A. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy. Clin. Immunol., 2002, 109 (3), 410-8.
4. Anderson, G. P. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet, 2008, 372 (9643), 1107-19.
5. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther., 2001, 69 (3), 89-95.
6. Bergeron, C.; Tulic, M. K.; Hamid, Q. Tools used to measure airway remodelling in research. Eur. Respir. J., 2007, 29 (3), 596-604.
7. Loukides, S.; Kostikas, K.; Bakakos, P. Non-invasive assessment of asthmatic inflammation: from bench to bedside. Curr. Med. Chem., 2011,18 (10), 1413-4.
8. Papaporfyriou, A.; Tseliou, E.; Loukides, S.; Kostikas, K.; Bakakos, P. Noninvasive evaluation of airway inflammation in patients with severe asthma. Ann. Allergy Asthma Immunol., 2013, 110 (5), 316-21.
9. Garn, H.; Renz, H. Epidemiological and immunological evidence for the hygiene hypothesis. Immunobiology, 2007, 212 (6), 441-52.
10. Wenzel, S. E. Complex phenotypes in asthma: current definitions. Pulm. Pharmacol. Ther., 2013, 26 (6), 710-5.
11. Ray, A.; Oriss, T. B.; Wenzel, S. E. Emerging molecular phenotypes of asthma. Am. J. Physiol. Lung Cell Mol. Physiol., 2015, 308 (2), L130-L140.
12. Shaheen, S. O. Changing patterns of childhood infection and the rise in allergic disease. Clin. Exp. Allergy, 1995, 25 (11), 1034-7.
13. Agache, I.; Akdis, C.; Jutel, M.; Virchow, J. C. Untangling asthma phenotypes and endotypes. Allergy, 2012, 67 (7), 835-46.
14. Bakakos, P.; Schleich, F.; Alchanatis, M.; Louis, R. Induced sputum in asthma: from bench to bedside. Curr. Med. Chem., 2011, 18 (10), 1415-22.
15. Haldar, P.; Pavord, I. D.; Shaw, D. E.; Berry, M. A.; Thomas, M.; Brightling, C. E.; Wardlaw, A. J.; Green, R. H. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med., 2008, 178 (3), 218-24.
16. Hastie, A. T.; Moore, W. C.; Meyers, D. A.; Vestal, P. L.; Li, H.; Peters, S. P.; Bleecker, E. R. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J. Allergy Clin. Immunol., 2010, 125 (5), 1028-1036 e13.
17. Kupczyk, M.; Dahlen, B.; Sterk, P. J.; Nizankowska-Mogilnicka, E.; Papi, A.; Bel, E. H.; Chanez, P.; Howarth, P. H.; Holgate, S. T.; Brusselle, G.; Siafakas, N. M.; Gjomarkaj, M.; Dahlen, S. E. Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy, 2014, 69 (9), 1198-204.
18. Kupczyk, M.; ten Brinke, A.; Sterk, P. J.; Bel, E. H.; Papi, A.; Chanez, P.; Nizankowska-Mogilnicka, E.; Gjomarkaj, M.; Gaga, M.; Brusselle, G.; Dahlen, B.; Dahlen, S. E. Frequent exacerbators--a distinct phenotype of severe asthma. Clin. Exp. Allergy, 2014, 44 (2), 212-21.
19. Fleming, L.; Tsartsali, L.; Wilson, N.; Regamey, N.; Bush, A. Sputum inflammatory phenotypes are not stable in children with asthma. Thorax, 2012, 67 (8), 675-81.
20. Traister, R. S.; Uvalle, C. E.; Hawkins, G. A.; Meyers, D. A.; Bleecker, E. R.; Wenzel, S. E. Phenotypic and genotypic association of epithelial IL1RL1 to human TH2-like asthma. J. Allergy Clin. Immunol., 2015, 135 (1), 92-99 e10.
21. Zhang, X. Y.; Simpson, J. L.; Powell, H.; Yang, I. A.; Upham, J. W.; Reynolds, P. N.; Hodge, S.; James, A. L.; Jenkins, C.; Peters, M. J.; Lin, J. T.; Gibson, P. G. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin. Exp. Allergy, 2014, 44 (9), 1137-45.
22. Schleich, F. N.; Chevremont, A.; Paulus, V.; Henket, M.; Manise, M.; Seidel, L.; Louis, R. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur. Respir. J., 2014, 44 (1), 97-108.
23. Kostikas, K.; Zervas, E.; Gaga, M. Airway and systemic eosinophilia in asthma: does site matter? Eur. Respir. J., 2014, 44 (1), 14-6.
24. Kostikas, K.; Minas, M.; Papaioannou, A. I.; Papiris, S.; Dweik, R. A. Exhaled nitric oxide in asthma in adults: the end is the beginning? Curr. Med. Chem., 2011, 18 (10), 1423-31.
25. Bessa, V.; Tseliou, E.; Bakakos, P.; Loukides, S. Noninvasive evaluation of airway inflammation in asthmatic patients who smoke: implications for application in clinical practice. Ann. Allergy Asthma Immunol., 2008, 101 (3), 226-32; quiz 232-4, 278.
26. Gratziou, C.; Lignos, M.; Dassiou, M.; Roussos, C. Influence of atopy on exhaled nitric oxide in patients with stable asthma and rhinitis. Eur. Respir. J., 1999, 14 (4), 897-901.
27. Berry, M. A.; Shaw, D. E.; Green, R. H.; Brightling, C. E.; Wardlaw, A. J.; Pavord, I. D. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clin. Exp. Allergy, 2005, 35 (9), 1175-9.
28. Schleich, F. N.; Seidel, L.; Sele, J.; Manise, M.; Quaedvlieg, V.; Michils, A.; Louis, R. Exhaled nitric oxide thresholds associated with a sputum eosinophil count >/=3% in a cohort of unselected patients with asthma. Thorax, 2010, 65 (12), 1039-44.
29. Dweik, R. A.; Boggs, P. B.; Erzurum, S. C.; Irvin, C. G.; Leigh, M. W.; Lundberg, J. O.; Olin, A. C.; Plummer, A. L.; Taylor, D. R. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am. J. Respir. Crit. Care Med., 2011, 184 (5), 602-15.
30. Haldar, P.; Pavord, I. D. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J. Allergy Clin. Immunol., 2007, 119 (5), 1043-52; quiz 1053-4.
31. Wenzel, S. E.; Schwartz, L. B.; Langmack, E. L.; Halliday, J. L.; Trudeau, J. B.; Gibbs, R. L.; Chu, H. W. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am. J. Respir. Crit. Care Med., 1999, 160 (3), 1001-8.
32. Polosa, R.; Thomson, N. C. Smoking and asthma: dangerous liaisons. Eur. Respir. J., 2013, 41 (3), 716-26.
33. Moore, W. C.; Meyers, D. A.; Wenzel, S. E.; Teague, W. G.; Li, H.; Li, X.; D'Agostino, R., Jr.; Castro, M.; Curran-Everett, D.; Fitzpatrick, A. M.; Gaston, B.; Jarjour, N. N.; Sorkness, R.; Calhoun, W. J.; Chung, K. F.; Comhair, S. A.; Dweik, R. A.; Israel, E.; Peters, S. P.; Busse, W. W.; Erzurum, S. C.; Bleecker, E. R. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am. J. Respir. Crit. Care Med., 2010, 181 (4), 315-23.
34. Desai, D.; Newby, C.; Symon, F. A.; Haldar, P.; Shah, S.; Gupta, S.; Bafadhel, M.; Singapuri, A.; Siddiqui, S.; Woods, J.; Herath, A.; Anderson, I. K.; Bradding, P.; Green, R.; Kulkarni, N.; Pavord, I.; Marshall, R. P.; Sousa, A. R.; May, R. D.; Wardlaw, A. J.; Brightling, C. E. Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am. J. Respir. Crit. Care Med., 2013, 188 (6), 657-63.
35. Al-Samri, M. T.; Benedetti, A.; Prefontaine, D.; Olivenstein, R.; Lemiere, C.; Nair, P.; Martin, J. G.; Hamid, Q. Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: A prospective study using multiple samples. J. Allergy Clin. Immunol., 2010, 125 (5), 1161-1163 e4.
36. Jackson, D. J.; Gangnon, R. E.; Evans, M. D.; Roberg, K. A.; Anderson, E. L.; Pappas, T. E.; Printz, M. C.; Lee, W. M.; Shult, P. A.; Reisdorf, E.; Carlson-Dakes, K. T.; Salazar, L. P.; DaSilva, D. F.; Tisler, C. J.; Gern, J. E.; Lemanske, R. F., Jr. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med., 2008, 178 (7), 667-72.
37. Gibson, P. G.; McDonald, V. M.; Marks, G. B. Asthma in older adults. Lancet, 2010, 376 (9743), 803-13.
38. Wenzel, S. E. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat. Med., 2012, 18 (5), 716-25.
39. Dixon, A. E.; Pratley, R. E.; Forgione, P. M.; Kaminsky, D. A.; Whittaker-Leclair, L. A.; Griffes, L. A.; Garudathri, J.; Raymond, D.; Poynter, M. E.; Bunn, J. Y.; Irvin, C. G. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. J. Allergy Clin. Immunol., 2011, 128 (3), 508-15 e1-2.
40. O'Neil, S. E.; Lundback, B.; Lotvall, J. Proteomics in asthma and COPD phenotypes and endotypes for biomarker discovery and improved understanding of disease entities. J. Proteomics, 2011, 75 (1), 192-201.
41. Olin, J. T.; Wechsler, M. E. Asthma: pathogenesis and novel drugs for treatment. BMJ, 2014, 349, g5517.
42. Blumchen, K.; Kallinich, T.; Hamelmann, E. Interleukin-5: a novel target for asthma therapy. Expert. Opin. Biol. Ther., 2001, 1 (3), 433-53.
43. Hallstrand, T. S.; Moody, M. W.; Wurfel, M. M.; Schwartz, L. B.; Henderson, W. R., Jr.; Aitken, M. L. Inflammatory basis of exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med., 2005, 172 (6), 679-86.
44. Lugogo, N. L.; Kraft, M.; Dixon, A. E. Does obesity produce a distinct asthma phenotype? J. Appl. Physiol. (1985), 108 (3), 729-34.
45. Jatakanon, A.; Uasuf, C.; Maziak, W.; Lim, S.; Chung, K. F.; Barnes, P. J. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med., 1999, 160 (5 Pt 1), 1532-9.
46. Bel, E. H.; Wenzel, S. E.; Thompson, P. J.; Prazma, C. M.; Keene, O. N.; Yancey, S. W.; Ortega, H. G.; Pavord, I. D. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med., 2014, 371 (13), 1189-97.
47. Pavord, I. D.; Korn, S.; Howarth, P.; Bleecker, E. R.; Buhl, R.; Keene, O. N.; Ortega, H.; Chanez, P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet, 2012, 380 (9842), 651-9.
48. Wagener, A. H.; de Nijs, S. B.; Lutter, R.; Sousa, A. R.; Weersink, E. J.; Bel, E. H.; Sterk, P. J. External validation of blood eosinophils, FENO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax, 2015, 70 (2), 115-20.
49. Corren, J.; Lemanske, R. F.; Hanania, N. A.; Korenblat, P. E.; Parsey, M. V.; Arron, J. R.; Harris, J. M.; Scheerens, H.; Wu, L. C.; Su, Z.; Mosesova, S.; Eisner, M. D.; Bohen, S. P.; Matthews, J. G. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med., 2011, 365 (12), 1088-98.
50. Brusselle, G. G.; Vanderstichele, C.; Jordens, P.; Deman, R.; Slabbynck, H.; Ringoet, V.; Verleden, G.; Demedts, I. K.; Verhamme, K.; Delporte, A.; Demeyere, B.; Claeys, G.; Boelens, J.; Padalko, E.; Verschakelen, J.; Van Maele, G.; Deschepper, E.; Joos, G. F. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebocontrolled trial. Thorax, 2013, 68 (4), 322-9.
51. Kreindler, J. L.; Steele, C.; Nguyen, N.; Chan, Y. R.; Pilewski, J. M.; Alcorn, J. F.; Vyas, Y. M.; Aujla, S. J.; Finelli, P.; Blanchard, M.; Zeigler, S. F.; Logar, A.; Hartigan, E.; Kurs-Lasky, M.; Rockette, H.; Ray, A.; Kolls, J. K. Vitamin D3 attenuates Th2 responses to Aspergillus fumigatus mounted by CD4+ T cells from cystic fibrosis patients with allergic bronchopulmonary aspergillosis. J. Clin. Invest., 2010, 120 (9), 3242-54